Navigation Links
FDA Advisory Committee Votes in Favor of Approval of Fospropofol Disodium Injection for Sedation
Date:5/7/2008

WOODCLIFF LAKE, N.J., May 7 /PRNewswire/ -- Eisai Corporation of North America and its U.S. subsidiary, MGI PHARMA, INC., today announced that the U.S. Food and Drug Administration (FDA) Advisory Committee on Anesthetic and Life Support Drugs (ALSDAC) has voted 6 to 3 in favor (with one abstention) of approval of fospropofol disodium injection for use as an intravenous sedative-hypnotic agent for sedation in adult patients undergoing diagnostic or therapeutic procedures.

The Committee recommended use of fospropofol disodium injection to health care providers who are appropriately trained. Further, the Committee recommended additional studies be conducted in specific patient populations, including those with a variety of comorbidities, for example, in patients who weigh less than 60 kg and the elderly.

"We are encouraged by ALSDAC's support of the efficacy and safety results of fospropofol disodium demonstrated in our clinical studies, and we look forward to continuing our discussions with FDA as they finalize their review of our application," said Mary Lynne Hedley, PhD, Executive Vice President of Eisai Corporation of North America. "We believe the clinical trial data support the use of this product by anesthesiologists and nonanesthesia health care professionals."

FDA reviewers will consider ALSDAC's recommendation in its review of the NDA for fospropofol disodium injection. The FDA is not bound by its Advisory Committees' recommendations.

Data from one Phase II and one Phase III trial in patients undergoing colonoscopy, a Phase III trial in patients undergoing bronchoscopy, and an open-label study in patients undergoing a variety of minor surgical procedures form the foundation of the fospropofol disodium injection NDA. In total, data from 21 clinical studies involving 1,611 individuals are included in the application. The clinical trials were conducted by nonanesthesia health care professionals, and study drugs were administered by medical personnel as dictated by local investigative site guidelines.

"Fospropofol disodium injection was designed to help meet the need for new minimal to moderate sedation agents, and therefore is representative of our human health care mission to address the unmet medical needs of patients," said Hajime Shimizu, Chairman and CEO, Eisai Corporation of North America.

About Fospropofol Disodium Injection

Fospropofol disodium injection is a proprietary water-soluble prodrug of propofol that, after intravenous injection, is converted by an enzyme (alkaline phosphatase) in the body into propofol. Fospropofol disodium injection is a product candidate in development for sedation of patients undergoing therapeutic or diagnostic procedures. Fospropofol disodium injection has not yet been approved for marketing by the Food and Drug Administration or any other regulatory agencies.

About Eisai Corporation of North America

Eisai Corporation of North America is a wholly-owned subsidiary of Eisai Co., Ltd., a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Eisai focuses its efforts in three therapeutic areas: neurology, gastrointestinal disorders and oncology/critical care.

Eisai Corporation of North America supports the activities of its operating companies in North America. These operating companies include: Eisai Research Institute of Boston, Inc., a discovery operation with strong organic chemistry capabilities; Morphotek, Inc., a biopharmaceutical company specializing in the development of therapeutic monoclonal antibodies; Eisai Medical Research Inc., a clinical development group; Eisai Inc., a commercial operation with manufacturing and marketing/sales functions; MGI PHARMA, INC.; and Eisai Machinery U.S.A., which markets and maintains pharmaceutical manufacturing machinery. For more information about Eisai, please visit http://www.eisai.com.

About MGI PHARMA, INC.

MGI PHARMA, INC., a wholly-owned subsidiary of Eisai Corporation of North America, is a biopharmaceutical company focused in oncology and acute care that acquires, researches, develops, and commercializes proprietary products that address the unmet needs of patients. For more information about MGI PHARMA, INC., please visit http://www.mgipharma.com.


'/>"/>
SOURCE Eisai Corporation of North America
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. DuPont Strengthens Commitment to Responsible Science with New Biotech Advisory Panel Members
2. Richard A. Schatz, M.D. Joins Cardiums Scientific Advisory Board
3. BioNanomatrix Announces Appointment of Paul R. Selvin to Its Scientific Advisory Board
4. Campbell Alliance Adds Doug Linton, Former Cardinal Health Executive, to Executive Advisory Group
5. NexGenix Pharmaceuticals Presents Data on a Novel Small Molecule Inhibitor of Heat Shock Protein 90 (Hsp90) at the Annual Meeting of the American Association for Cancer Research (AACR); Scientific Advisory Board Chairman Tyler Jacks Named President-elect
6. Gene Network Sciences Names New CSO and Announces New Scientific Advisory Board
7. Egenix, Inc. Appoints Dr. Daniel Petrylak Chairman of Scientific Advisory Board
8. Prestigious Scientific Leaders Join InterWest Advisory Committee
9. febit Forms Scientific Advisory Board
10. Media Advisory - Oncolytics Biotech Inc. to Present at BioSquare 2008
11. John E. Leonard, Ph.D., Former Biogen Idec Antibody Development Executive, Joins the Scientific Advisory Board of Vaccinex, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... June 27, 2016  Global demand for enzymes ... through 2020 to $7.2 billion.  This market includes ... cleaning products, biofuel production, animal feed, and other ... and biocatalysts). Food and beverages will remain the ... increasing consumption of products containing enzymes in developing ...
(Date:6/27/2016)... CA (PRWEB) , ... June 27, 2016 , ... ... for clinical trials, announced today the Clinical Reach Virtual Patient Encounter CONSULT ... care circle with the physician and clinical trial team. , Using the CONSULT module, ...
(Date:6/27/2016)... 27, 2016   Ginkgo Bioworks , a leading ... was today awarded as one of the World ... world,s most innovative companies. Ginkgo Bioworks is engineering ... real world in the nutrition, health and consumer ... with customers including Fortune 500 companies to design ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Researchers at ... most commonly-identified miRNAs in people with peritoneal or pleural mesothelioma. Their findings are the ... read it now. , Diagnostic biomarkers are signposts in the blood, lung fluid ...
Breaking Biology Technology:
(Date:6/16/2016)... 16, 2016 The global ... to reach USD 1.83 billion by 2024, according ... Inc. Technological proliferation and increasing demand in commercial ... to drive the market growth.      ... The development of advanced multimodal techniques for biometric ...
(Date:6/7/2016)... , June 7, 2016  Syngrafii Inc. ... a business relationship that includes integrating Syngrafii,s patented ... branch project. This collaboration will result in greater ... the credit union, while maintaining existing document workflow ... http://photos.prnewswire.com/prnh/20160606/375871LOGO ...
(Date:6/2/2016)... Perimeter Surveillance & Detection Systems, ... Infrastructure, Support & Other Service  The latest ... comprehensive analysis of the global Border Security market ... of $17.98 billion in 2016. Now: In ... in software and hardware technologies for advanced video surveillance. ...
Breaking Biology News(10 mins):